By David Wallace Silence Therapeutics reported that divesiran met the primary endpoint of the randomized Phase 2 SANRECO trial. Among 48 phlebotomy-dependent polycythemia vera patients, 88% of those receiving divesiran maintained hematocrit below 45% without phlebotomy during weeks 18 through 36, compared with 19% on placebo. The difference was statistically significant. What the Phase 2 […]
Breakthrough CALR Therapy Shows High Response Rate in ET
by David Wallace New Treatment Targets Root Cause of ET: INCA033989 Trial Shows Powerful Results June 15, 2025 – EHA Congress, Milan Incyte has announced positive, late-breaking data from the first clinical studies of its experimental therapy INCA033989—an antibody designed to precisely target a genetic driver of disease in patients with Essential Thrombocythemia (ET). The […]
Phase 3 Clinical Trial for Polycythemia Vera
Unfortunately for some polycythemia vera (PV) patients, current treatment options may not be fully effective or well-tolerated and may cause serious side effects. But a promising investigational treatment is currently being clinically evaluated. Rusfertide, also known as PTG-300, is an investigational new drug designed to slow the release of iron into the bone marrow. The […]
Is there a Connection between MPNs and Autoimmune Diseases?
by David Wallace Patients are Asking – Episode 2 of 3 In this interview with MPN expert, Dr. Angela Fleischman, we discuss the latest treatments for myelofibrosis (MF) and when a clinical trial should be considered. Research has linked MPNs to a pre-disposition to autoimmune disorders such as Lupus, Crohn’s disease and Psoriasis just to […]